PathSensors, Inc., a rapidly growing, Baltimore-based biotechnology company focused on delivering pathogen detection solutions, announced today that it has been awarded a $7.2 million contract from the Department of Defense – Washington Headquarters Services to provide CANARY reagents and technical support to Department of Defense Facilities in the National Capital Region. The program includes the manufacture of reagents, equipment support and the development of products for new and emerging threats. The contract extends through 2023.
Non-disclosure agreements (with potential co-owners/joint ventures/investors and employees)
Worker classifications (exempt vs non-exempt; W2 or 1099)
Employment contracts
Lease or distributor agreements
Customer agreements (for Beta testing and beyond)
CRADA’s and technology transfer agreements
Learn about these topics and more through the December 13th PathFinder Innovation Program. (There is no charge to attend in person or by videoconference. However, pre-registration by NOON, 12/12is required).
1:00-1:30 p.m. Networking Lunch
1:30-2:45 p.m.– Issues Overview (in person/by videoconference)
Speakers:
Anthony Millin, Esq. – Startups Chair, Shulman Rogers
Lynn Perry Parker, Esq. – Principal, LPP Law
2:45 p.m. – 1:1 Office Hours (in person/by videoconference)*
This program is cosponsored by BioHealth Innovation, Launch Workplaces, TEDCO and Montgomery County. It is open to anyone in the BioHealth Capital Region.
To register/For more information, email: BHI@BioHealthInnovation. *Participation in Overview Discussion (in person/by videoconference) is required to attend 1:1 office hours.
Results from a Phase 1 clinical trial evaluating the safety and immunogenicity of Emergent BioSolutions’ (NYSE:EBS) Zika vaccine, VLA1601, showed a favorable safety profile for all doses and schedules tested and encouraging immunogenic activity.
Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? business/commercialization plan, pitch deck, or idea?
Schedule your feedback session with BHI EIRs on one of the following dates:
12/12
2/13
3/20
5/22
(30 minute blocks of time beginning at 9:00 in the morning. If the morning slots are filled, more time will be allotted beginning at 1 p.m.)
Pre-registration is required; sign up here (“EIR resource”at BHI). For questions/more information, contact BHI.
As stated by Josh Wolfe, co-founder and managing partner at Lux Capital, “the gap between ‘sci-fi’ — that which was once imagined — and ‘sci-fact’ — that which becomes manifest and real — is shrinking.”
Between clinical objectives, financial concerns, patient needs and complex payer dynamics, there seem to be too few hours in the day for healthcare executives to address the diverse set of organizational goals they are tasked with accomplishing.
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today dosing of the first patient in the company’s Phase 3 clinical trial of uproleselan (GMI-1271) in relapsed/refractory AML. The trial’s protocol provides for administration of the investigational drug in combination with MEC (mitoxantrone, etoposide and ara-C) or in combination with FAI (fludarabine, ara-C and idarubicin), both of which are standard of care for this indication in the United States. In 2017, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to GlycoMimetics for uproleselan in this patient population. The company anticipates the initiation of two complementary Phase 2/3 trials from two leading clinical consortia in early 2019.
With preparedness solutions that address emerging infectious diseases to chemical and biological threats, protecting and enhancing lives is at the heart of everything Emergent BioSolutions does. Emergent develops vaccines, therapeutics, and devices for some of the most notable diseases and threats in modern history, including Zika, Ebola and Anthrax.
Market conditions for venture funding remained very strong in the third quarter of 2018. Deal size and pre-money valuations across all equity rounds decreased slightly but still remained high by historical standards. Median pre-money valuations inched down across the board in Q3 2018. The decline in median amounts raised was more significant, with Series B financings taking the most significant hit, and with the median size falling nearly 50% from the prior quarter. However, more post-Series A financings were up rounds, reversing the decline seen in the first half of 2018.
The University System of Maryland (USM) is Maryland’s public higher education system, consisting of 11 degree-granting universities, two regional higher education centers and one environmental research institution. With approximately 170,000 students and 38,000 graduates each year, USM is the most significant producer of talented workers and educated citizens in Maryland. USM institutions, faculty, students and graduates attract billions of federal and privately funded research dollars to the state that support thousands of jobs. They also create hundreds of new companies. Combined, these activities enable USM to support one of America’s most vibrant economies.
Today, the Greater Washington Partnership unveiled the Blueprint For Regional Mobility, the first ever CEO-driven comprehensive strategy that binds the Capital Region and better connects residents in Baltimore, Washington and Richmond to opportunity.
This unified vision for the future of the region’s transportation system comes on the heels of Amazon’s commitment earlier this month to bring 25,000 jobs to the region. Executing on the seven solutions and 20 actions laid out in the Blueprint will fundamentally transform the way we move around the region, reversing our current disjointed system’s trajectory of worsening congestion and limiting access to essential destinations for many families in our region.
What comes to mind when you think about your body?
Most people might imagine an intricate network of blood vessels or the complex neural circuits of the brain. Or we might picture diagrams from the iconic medical textbook, Gray’s Anatomy.
Participants selected for cohort three will receive: *
A two-year fellowship – Includes a personal living stipend of up to $90,000/year depending on education and experience, along with health insurance and travel allowance
Lab access and research funding – In addition to unparalleled access to facilities, equipment, and expertise at Oak Ridge National Laboratory, fellows receive $200,000 of R&D funding to support collaboration opportunities with researchers across the lab.
Business mentors, entrepreneurial training, and networking – Participants receive access to experienced business mentors, entrepreneurial training programs, and exclusive networking opportunities. Innovators are also exposed to a wide range of leaders from academia, industry, government, and finance that can serve as advisors and partners.
*All support is subject to performance and availability of funds.
Eligibility criteria
For acceptance into the program, applicants:
Must have PhD or equivalent experience
Must be focused on energy or manufacturing innovation
Must leverage ORNL R&D capabilities and have an impact on the Department of Energy (DOE) or Tennessee Valley Authority (TVA) mission
Must be willing to relocate to the Knoxville-Oak Ridge area
Must be a US citizen or lawful permanent resident at time of application
